Recent developments of interest in cardiovascular medicine
Effectiveness of this personalized approach now under investigation
Panelists acknowledge difficulty generating stronger data in ultra-rare disease
Agency appears unswayed by mitochondria-targeting drug for rare cardioskeletal disease
Benefit in symptoms, functional outcomes remains to be seen for HU6
Cardiac myosin inhibitor linked to improvements in biomarkers in small study
Vast majority of trial participants responded to aficamten
Benefit of the nonsteroidal MRA otherwise consistent across FINEARTS-HF
Meta-analysis holds LGE higher than LVEF in identifying high-risk NIDCM
Study lays out common gaps in evidence both before and after approval